Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLV334 Dose Escalation in Moderate and Severe Traumatic Brain Injury
NCT00735085Phase 2Terminated
- Sponsor
- Abbott Laboratories
- Start
- Apr 2009
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of slv-334 in traumatic brain injury (TBI), sponsored by Abbott Laboratories. Started Apr 2009; status: terminated.
02
Drugs
slv-334
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT00735085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00735085.